Mecasermin

BioDrugs

Volumn 22, Issue 3, 2008, Pages 177-188

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Mecasermin, pharmacodynamics; Mecasermin, pharmacokinetics; Mecasermin, therapeutic use; Short stature

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ANOREXIA NERVOSA; ARTHRALGIA; BONE PAIN; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EVENING DOSAGE; GENE DELETION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPOACUSIS; HYPOGLYCEMIA; INJECTION SITE HYPERTROPHY; INJECTION SITE LIPOHYPERTROPHY; INTRACRANIAL HYPERTENSION; LONG TERM CARE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NEPHROLITHIASIS; OBESITY; ORTHOPEDIC MANIPULATION; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SLEEP APNEA SYNDROME; SNORING; THYMUS HYPERPLASIA; TONSIL CELL; TONSILLECTOMY; UNITED STATES;

ANIMALS; ANOREXIA NERVOSA; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GROWTH DISORDERS; HIV WASTING SYNDROME; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OBESITY;

EID: 43749111749     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822030-00004     Document Type: Review

References (44)

1. Backeljauw PF, Chernausek SD. Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans. Horm Res 2006; 65 Suppl. 1: 21-7
2. Clark RG. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm Res 2004; 62 Suppl. 1: 93-100
3. Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisome in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80 (3): 869-74
4. Mauras N, Martinez V, Rini A, et al. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000 Sep; 85 (9): 3036-42
5. Kaplan SA, Cohen P. Review: the somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007 Dec; 92 (12): 4529-35
6. Tercica, Inc. Increlex™ (mecasermin [rDNA origin] injection): US prescribing information [online]. Available from URL: http://www.tercica.com [Accessed 2008 Mar 4]
7. European Medicines Agency. Mecasermin: scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Mar 3]
8. Rosenfeld RG. IGF-I therapy in growth disorders. Eur J Endocrinol 2007 Aug; 157 Suppl. 1: S57-60
9. Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet 2006 Aug 12; 368 (9535): 612-6
10. Dunger D, Yuen K, Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004; 62 Suppl. 1: 101-7
11. Mauras N, Martha PM, Quarmby V, et al. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery. Am J Physiol Endocrinol Metab 1997 Apr; 35: E628-33
12. European Medicines Agency. Mecasermin: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Mar 3]
13. Schoenle E, Zapf J, Humbel RE. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 1982 Mar 18; 296 (5854): 252-3
14. Tomas FM, Knowles SE, Chandler CS, et al. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol 1993 Jun; 137 (3): 413-21
15. Douglas RG, Gluckman PD, Ball K, et al. The effects of infusion of insulin-like growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs. J Clin Invest 1991 Aug; 88 (2): 614-22
16. Jacob R, Barrett E, Plewe G, et al. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 1989 May; 83 (5): 1717-23
17. Zapf J, Hauri C, Waldvogel M, et al. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 1986 Jun; 77 (6): 1768-75
18. Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007 Mar; 92 (3): 902-10
19. Backeljauw PF, Underwood LE. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001 Apr; 86 (4): 1504-10
20. Guevara-Aguirre J, Guevara-Aguirre M, Rosenbloom AL. Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I. Acta Paediatr 2006 Feb; 95 (2): 199-202
21. Mauras N, Horber FF, Haymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 1992 Nov; 75 (5): 1192-7
22. Laager R, Ninnis R, Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 1993 Oct; 92 (4): 1903-9
23. Turkalj I, Keller U, Ninnis R, et al. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 1992 Nov; 75 (5): 1186-91
24. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987 Jul 16; 317 (3): 137-40
25. Mauras N. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 1995 Sep; 80 (9): 2633-7
26. Fervenza FC, Friedlaender MM, Ike JO, et al. Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure. Ren Fail 1998; 20 (2): 349-56
27. FDA. Center for Drug Evaluation and Research approval package for: application number NDA 21-839: medical review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2005/021839_S000_Increlex_MedR.pdf [Accessed 2008 Mar 3]
28. Backeljauw PF, Underwood LE, and the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 1996 Sep; 81 (9): 3312-7
29. Underwood LE, Backeljauw P, Duncan V. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr Suppl. 1999 Feb; 88 (428): 182-4
30. Riedl S, Frisch H. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab 2006 Mar; 19 (3): 229-36
31. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992 Oct; 121 (4): 641-6
32. Walker JL, Ginalska-Malinowska M, Romer TE, et al. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 1991 May 23; 324 (21): 1483-8
33. Thrailkill KM, Quattrin T, Baker L, et al. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. Diabetes Care 1999 Apr; 22 (4): 585-92
34. Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF- binding protein system. J Clin Endocrinol Metab 1997 Apr; 82 (4): 1181-7
35. Quattrin T, Thrailkill K, Baker L, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM: effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997 Mar; 20 (3): 374-80
36. Moses AC, Young SCJ, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996 Jan; 45: 91-100
37. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 Dec 1; 125 (11): 865-72
38. Lee PDK, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996 Aug; 81 (8): 2968-75
39. Nguyen B-Y, Clerici M, Venzon DJ, et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998 May 28; 12 (8): 895-904
40. Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002 Jun; 87 (6): 2883-91
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
42. Thompson JL, Butterfield GE, Gylfadottir UK, et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 1998 May; 83 (5): 1477-84
43. Bucuvalas JC, Chernausek SD, Alfaro MP, et al. Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2001 Nov; 33 (5): 576-81
44. Kudsk KA, Mowatt-Larssen C, Bukar J, et al. Effect of recombinant human insulin-like growth factor I and early total parenteral nutrition on immune depression following severe head injury. Arch Surg 1994 Jan; 129: 66-71